Cost–effectiveness of catch-up programs in human papillomavirus vaccination

References

• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol.32(Suppl. 1) S16–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88(1), 63–73 (2003).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer121(3), 621–632 (2007).
   PubMed Web of Science ®Google Scholar
• von Krogh G. Management of anogenital warts (condylomata acuminata). Eur. J. Dermatol.11(6), 598–603 (2001).
   PubMed Web of Science ®Google Scholar
• Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine24(Suppl. 3), S3/1–10 (2006).
   Google Scholar
• Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol. Biomarkers Prev.14(9), 2191–2199 (2005).
   PubMed Web of Science ®Google Scholar
• Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet364(9430), 249–256 (2004).
   PubMed Web of Science ®Google Scholar
• Raffle AE, Alden B, Quinn M, Babb PJ, Brett MT. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. Br. J. Med.326(7395), 901 (2003).
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control8(5), 755–763 (1997).
   PubMed Web of Science ®Google Scholar
• Hu Dk, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am. J. Obstet. Gynecol.198(5), 500–507 (2008).
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine24(Suppl. 3), S3/35–S3/41 (2006).
   PubMedGoogle Scholar
• Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int. J. STD AIDS9(10), 571–578 (1998).
   PubMed Web of Science ®Google Scholar
• Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y. Estimation of the impact of genital warts on health-related quality of life. Sex. Transm. Infect.84(3), 161–166 (2008).
   PubMed Web of Science ®Google Scholar
• Woodhall SC, Jit M, Cai C, Ramsey T, Zia S, Crouch S. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex. Transm. Dis.36(8), 515–521 (2009).
   PubMed Web of Science ®Google Scholar
• FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356(19), 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• FUTURE II study group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J. Infect. Dis.196(10), 1438–1446 (2007).
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet369(9576), 1861–1868 (2007).
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356(19), 1928–1943 (2007).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Eidgenossische Kommission fur Impffragen. Recommandation pour une vaccination de base des adolescentes contre le cancer du col de l’uterus et autres maladies causees par le virus du papillome humain (HPV). Commission Fédérale pour les Vaccinations, Berne, Switzerland (2007).
   Google Scholar
• Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev.28(1), 2888–2100 (2006).
   Google Scholar
• Ferko N, Postma M, Gallivan S, Kruzikas D, Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine26(Suppl. 5) F3–F15 (2008).
   Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Structural differences among cost–effectiveness models of human papillomavirus vaccines. Expert Rev. Vaccines7(7), 895–913 (2008).
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost–effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics26(3), 191–215 (2008).
   PubMed Web of Science ®Google Scholar
• Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics27(2), 127–147 (2009).
   PubMed Web of Science ®Google Scholar
• Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost–effectiveness analyses of human papillomavirus vaccination. Lancet Infect. Dis.7(4), 289–296 (2007).
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG115(8), 947–956 (2008).
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis.13(1), 28–41 (2007).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost–effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine26(1), 128–139 (2007).
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Br. J. Med.337, a769 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med.359(8), 821–832 (2008).
   PubMed Web of Science ®Google Scholar
• Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG. A cost–effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health4(3), 165–175 (2007).
   PubMed Web of Science ®Google Scholar
• Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Cost–effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine26(44), 5654–5661 (2008).
   PubMed Web of Science ®Google Scholar
• Dasbach E, Largeron N, Elbasha E. Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev. Pharmacoecon. Outcomes Res.8(5), 491–500 (2008).
   PubMedGoogle Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine26(Suppl. 10), K76–K86 (2008).
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer118(12), 3030–3044 (2006).
   PubMed Web of Science ®Google Scholar
• Pou AM, Rimell FL, Jordan JA, Shoemaker DL, Johnson JT, Barua P. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann. Otol. Rhinol. Laryngol.104(10 Pt 1), 758–762 (1995).
   PubMed Web of Science ®Google Scholar
• Rimell FL, Shoemaker DL, Pou AM, Jordan JA, Post JC, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope107(7), 915–918 (1997).
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avil M, Wheeler CM, Perez G, Koutsky LA. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet369(9574), 1693–1702 (2007).
   PubMed Web of Science ®Google Scholar
• Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE. Pregnancy outcome in women before and after cervical conisation: population based cohort study. Br. J. Med.337, a1343 (2008).
   PubMedGoogle Scholar
• Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Br. J. Med.337, a1284 (2008).
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet367(9509), 489–498 (2006).
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J. Infect. Dis.196, 1438–1446 (2007).
   PubMed Web of Science ®Google Scholar
• Pagliusi SR, Teresa AM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine23(5), 569–578 (2004).
   PubMed Web of Science ®Google Scholar
• Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CMM. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin.5(10), 696–704 (2009).
   PubMed Web of Science ®Google Scholar
• Ekwueme DU, Chesson HW, Zhang KB, Balamurugan A. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis – United States, 2003. Cancer113(10 Suppl.), 2936–2945 (2008).
   PubMed Web of Science ®Google Scholar
• Insinga RP. Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues16(5), 236–242 (2006).
   PubMed Web of Science ®Google Scholar
• Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donavan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex. Transm. Infect.85(7), 499–502 (2009).
   PubMed Web of Science ®Google Scholar